{"prompt": "['82', 'MC1488', 'Appendix VI: List of prohibited concomitant medications and concomitant medications', 'requiring caution', 'DISALLOWED MEDICATIONS AND MEDICATIONS TO BE', 'ADMINISTERED WITH CAUTION', 'Formal drug-drug interaction studies have not yet been performed with AZD1775, therefore, the', 'potential for drug-drug interaction described in this protocol are based on findings from in vitro', 'studies and clinical experience.', 'In vitro data has shown that AZD1775 is metabolised predominantly by CYP3A4, with an', 'FMO3 and/or FMO5 component. As a result, there is potential for the exposure of AZD1775 to', 'be effected by drugs which inhibit or induce the metabolism of CYP3A4. In the clinic,', 'coadministration of AZD1775 with the moderate CYP3A4 inhibitor, aprepaitant, resulted in a', '60% increase in the plasma levels of AZD1775. Drugs known to be moderate to strong', 'inhibitors/inducers of CYP3A4 are therefore prohibited for use in the current study, including', 'aprepitant.', 'In vitro data suggests that AZD1775 may be a weak reversible inhibitor of CYP2C19 (IC50 12', 'uM). Caution should therefore be exercised when AZD1775 is coadministered with agents that', 'are sensitive substrates of CYP2C19, or substrates of this enzyme with a narrow therapeutic', 'range.', 'Based on in vitro studies, AZD1775 has been show to be a weak reversible inhibitor (IC50 14', 'M) and a time-dependent inhibitor of CYP3A4 (Kinact 0.061/min, Ki 6.04 M). The full impact', 'of the time dependent inhibition is currently unknown, however, modelling data has predicted an', '8-10 fold increase in the exposure of sensitive CYP3A4 substrates when administered with', 'AZD1775 (250 mg BID for 5 doses). To date, no significant DDI effects have been reported in', 'the clinic that may be related to the TDI finding. However, sensitive CYP3A4 substrates or', 'substrates of CYP3A4 with a narrow therapeutic window are prohibited.', 'AZD1775 has been shown to be a weak inducer of CYP1A2 in vitro (39% increase in activity of', 'positive control). Given the nature of the AZD1775 dosing schedule, however, the risk of', 'induction in the clinic is considered low. No specific precautions are recommended at this time,', 'except to be initially vigilant when using substrates of CYP1A2 with a narrow therapeutic range.', 'Transporter studies (in vitro) have shown that AZD1775 is both a substrate and inhibitor (IC50 20', 'M) of P-gp. Maximum impact of these finding is likely to occur for drugs administered orally at', 'the same time as AZD1775. Caution should therefore be exercised when agents that are', 'inhibitors or substrates of P-gp are administered concomitantly with AZD1775.', 'Recent invitro transporter studies have shown AZD1775 to be an inhibitor of BCRP (IC50 5.1', 'M). This finding is particularly relevant for drugs administered orally where exposure is', 'normally limited by BCRP-mediated efflux, in particular some statins. Modelling has predicted', 'a substantial increase in the exposure of Atorvastatin when coadministered with AZD1775 and', 'the use of Atoravastatin is therefore prohibited in the current study. Other drugs where the', 'disposition is mediated via BCRP should be administered with caution, dose modification', 'considered or substituted by an alternative drug.', 'Herbal preparations/medications can be substrates, inhibitors and inducers, similar to any', 'registered medication. Herbal preparations are therefore not allowed throughout the study.']['83', 'MC1488 WEE1', 'MCCC', \"These herbal medications include, but are not limited to: St. John's wort, kava, ephedra (ma\", 'huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.', \"In addition, any other drugs should be avoided at the Investigator's discretion if, in their opinion,\", 'the co-administration with AZD1775 may increase the risk of a clinically significant drug', 'interaction.', 'A list of the main CYP3A4 substrates, inhibitors (strong and moderate) and inducers, CYP2C19', 'substrates, P-gp substrates and inhibitors and BCRP substrates are shown below. This is not an', 'exhaustive list and further details can be found at Expert Opin. Drug Metab. Toxicol. (2013)', '9(6):737-751.']\n\n###\n\n", "completion": "END"}